Trial Profile
A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Derivative Glimepiride on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus (T2DM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms RENALIS
- 08 Sep 2020 Primary endpoint (Changes from baseline following 8-week treatment with linagliptin vs glimepiride on fasting and postprandial renal hemodynamics, measured as GFR / ERPF (determined by inulin/para-aminohippuric-acid clearance) has not been met according to the results published in the Diabetes care
- 08 Sep 2020 Results comparing the effects of the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin with those of a sulfonylurea on renal physiology in metformin-treated patients with type 2 diabetes mellitus (T2DM) published in the Diabetes Care
- 16 May 2016 Status changed from active, no longer recruiting to completed.